29/05/2016 07:37:12 1-888-992-3836 (toll free) Free Membership Login

Merck News (NYSE:MRK)

DateTimeSource
Headline
05/27/20167:46AMBWMerck Receives Positive CHMP Opinion for ZEPATIER™ (elbasvir and grazoprevir) in the European Union
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of ZEPATIER™ (elbasvir and grazoprevir), an investigational, once-daily, fixed-dose... More...>>
05/26/20168:08AMBWCorporate Social Responsibility Related News Releases and Story Ideas for Reporters, Bloggers and Media Outlets
Following are the latest Corporate Social Responsibility news releases and story ideas available from Business Wire. These recaps, curated by Business Wire, provide reporters and bloggers around the globe instant access to the latest news releases, providing relevant and trending content to share with their audiences... More...>>
05/24/20162:35PMBWMerck Announces Third-Quarter 2016 Dividend
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Board of Directors has declared a quarterly dividend of $0.46 per share of the company’s common stock for the third quarter of 2016. Payment will be made on July 8, 2016 to shareholders of record at the close of business on... More...>>
05/24/20161:31PMBWMSD Animal Health riceve l'approvazione all'immissione in commercio da parte dell'Agenzia europea per i medicinali per BRAVEC...
Il trattamento topico contro pulci e zecche è efficace per 12 settimane MSD Animal Health (conosciuta come Merck Animal Health negli Stati Uniti e in Canada) ha oggi annunciato che, a seguito del parere positivo da parte del Comitato per i medicinali veterinari (CVMP), l'Agenzia europea per i medicinali ha concesso l'autorizzazione... More...>>
05/24/201612:21PMBWMSD Animal Health erhält Marktzulassung der Europäischen Arzneimittelagentur für BRAVECTO™ (Fluralaner) Spot-On-Lösung ...
Spot-On-Behandlung für Flöhe und Zecken mit einer Wirkungszeit von 12 Wochen MSD Animal Health (in den USA und Kanada unter dem Namen Merck Animal Health bekannt) gab heute bekannt, dass die Europäischen Arzneimittelagentur nach einer positiven Stellungnahme des Ausschusses für Tierarzneimittel (CVMP) die Marktzulassung... More...>>
05/24/20169:20AMBWMSD Animal Health reçoit une autorisation de commercialisation de l'Agence européenne du médicament pour sa solution BRAVE...
Le traitement Spot-On contre les puces et les tiques est efficace pendant 12 semaines MSD Animal Health (connue sous le nom de Merck Animal Health aux États-Unis et au Canada) a annoncé aujourd'hui que, suite à un avis positif du Comité des médicaments à usage vétérinaire (CVMP), l’Agence européenne du médicament... More...>>
05/24/20168:00AMBWMerck to Present at the UBS Global Healthcare Conference
Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that Adam Schechter, executive vice president and president, Global Human Health, Merck, is scheduled to present at the UBS Global Healthcare Conference in New York on May 25, 2016 at 8:00 a.m. EDT. Investors, analysts, members of the... More...>>
05/24/20166:19AMBWMSD Animal Health Receives Marketing Approval from European Medicines Agency for BRAVECTO™ (fluralaner) Spot-On Solution fo...
Spot-On Treatment for Fleas and Ticks Effective For 12 Weeks MSD Animal Health (known as Merck Animal Health in the United States and Canada) today announced that, following a positive opinion from the Committee for Medicinal Products for Veterinary Use (CVMP), the European Medicine Agency has granted a marketing authorization... More...>>
05/23/20164:40PMDJNSamsung Targets U.S. Drug Market With Remicade Knockoff
SEOUL—Samsung Group said Tuesday its near-replica of Johnson & Johnson's blockbuster arthritis drug Remicade has been accepted for review by the U.S. Food and Drug Administration, marking the South Korean conglomerate's first attempt to sell drugs to Americans, alongside its popular smartphones and... More...>>
05/23/20169:00AMBWMerck Foundation Announces the Alliance to Advance Patient-Centered Cancer Care, a $15 Million Initiative to Improve Access t...
Merck Foundation Accepting Applications from Non-Profit Organizations The Merck Foundation announced today the launch of a new initiative, the Alliance to Advance Patient-Centered Cancer Care (the Alliance), to support programs aimed at improving timely access to patient-centered care and reduce disparities in cancer care... More...>>
05/19/20164:20PMDJNGermany's Bayer Breaks With Caution in Monsanto Bid
FRANKFURT—Two weeks after taking over as chief executive of Bayer AG, Werner Baumann has kicked off what could be the biggest foreign corporate takeover effort ever by a German company—a move that comes amid a broader effort to focus the pharmaceuticals and chemical giant more closely on its drugs, health and... More...>>
05/18/201610:27PMDJNNew Hope for Melanoma Patients -- Update
By Peter Loftus A new study reinforces the potential of a new class of expensive immune-boosting drugs to prolong the lives of people with a deadly form of skin cancer. An estimated 40% of 655 people who took Merck & Co.'s Keytruda in a clinical trial to treat advanced melanoma were still alive three years after... More...>>
05/18/20165:29PMDJNNew Hope for Melanoma Patients
By Peter Loftus A new study reinforces the potential of a new class of expensive immune-boosting drugs to prolong the lives of people with a deadly form of skin cancer. An estimated 40% of 655 people who took Merck & Co.'s Keytruda in a clinical trial to treat advanced melanoma were still alive three years after... More...>>
05/18/20165:19PMBWNew KEYTRUDA® (pembrolizumab) Data from KEYNOTE-006 & KEYNOTE-001 in Advanced Melanoma, Including Updated Survival Data, To ...
Final Overall Survival Data from KEYNOTE-006 To Be Presented at ASCO; KEYTRUDA, the First Anti-PD-1 Monotherapy to Demonstrate Overall Survival Compared to Ipilimumab, Shows Continued Benefit with Longer Follow-Up KEYNOTE-001 Findings Show Continued Benefit in Response Rates, Duration of Response, and Include New Three-Year... More...>>
05/16/20168:00AMBWNew KEYTRUDA® (pembrolizumab) Data at 2016 ASCO Annual Meeting Includes Three-Year Overall Survival Data in Melanoma & Updat...
Data at ASCO Evaluates KEYTRUDA As Single Agent and in Novel Combinations in More Than 15 Different Cancers, Including Several New Tumors Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that new and updated data investigating KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy... More...>>
05/12/20168:30AMBWMerck to Present Phase 3 Data on Investigational Medicines Ertugliflozin & MK-1293 at the 76th Scientific Sessions of the Ame...
Additional Analyses from the TECOS Cardiovascular Safety Trial of JANUVIA® (sitagliptin) Also to Be Presented Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that researchers will present data from clinical trials of its investigational diabetes pipeline, JANUVIA® (sitagliptin... More...>>
05/10/20161:54PMDJNU.S. Investigates Drugmaker Contracts With Pharmacy-Benefit Managers -- Update
By Peter Loftus Federal prosecutors are investigating drugmakers' contracts with companies that manage prescription benefits in the U.S., the latest sign of government scrutiny of how drug companies and industry middlemen do business. The U.S. Attorney's Office for the Southern District of New York has sent demands... More...>>
05/10/201612:24PMDJNU.S. Investigates Drugmaker Contracts With Pharmacy Benefit Managers
By Peter Loftus Federal prosecutors are investigating drugmakers' contracts with companies that manage prescription benefits in the U.S., the latest sign of government scrutiny of how drug companies and industry middlemen do business. The U.S. Attorney's Office for the Southern District of New York has sent demands... More...>>
05/05/201611:10AMDJNMerck Revenue Falls on Generic Competition, Currency -- 2nd Update
By Austen Hufford Merck & Co. posted a revenue decline as generic competition and currency fluctuations hurt its results. Merck said it expects 2016 adjusted earnings per share of between $3.65 and $3.77, compared with its previous projection of $3.60 to $3.75. It expects revenue to be between $39 billion and $40.2... More...>>
05/05/201610:07AMDJNMerck Revenue Falls on Generic Competition, Currency -- Update
By Austen Hufford Merck & Co. posted a revenue decline as generic competition and currency fluctuations hurt its results. Merck said it expects 2016 adjusted earnings per share of between $3.65 and $3.77, compared with its previous projection of $3.60 to $3.75. It expects revenue to be between $39 billion and $40.2... More...>>
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:34 V:us D:20160529 11:37:13